No Association of the TGF-β1 29T/C Polymorphism with Breast Cancer Risk in Caucasian and Asian Populations: Evidence from a Meta-Analysis Involving 55, 841 Subjects

  • Alqumber, Mohammed A.A. ;
  • Dar, Sajad Ahmad ;
  • Haque, Shafiul ;
  • Wahid, Mohd ;
  • Singh, Rohit ;
  • Akhter, Naseem
  • Published : 2014.11.06


The transforming growth factor-${\beta}1$ (TGF-${\beta}1$) gene 29 T/C polymorphism is thought to be associated with breast cancer risk. However, reports are largely conflicting and underpowered. We therefore conducted a meta-analysis of all available case-control studies relating the TGF-${\beta}1$ 29T/C polymorphism to the risk of developing breast cancer by including a total of 31 articles involving 24,021 cases and 31,820 controls. Pooled ORs were generated for the allele contrasts, with additive genetic, dominant genetic and recessive genetic models. Subgroup analysis was also performed by ethnicity for the TGF-${\beta}1$ 29T/C polymorphism. No association was found in the overall analysis (C vs T: OR=1.028, 95% CI=0.949-1.114, p-value 0.500; CC vs TC: OR= 1.022, 95% CI=0.963-1.085, p-value 0.478; CC vs TT: OR= 1.054, 95% CI=0.898-1.236, p-value 0.522; CC vs TT+ TC: OR= 1.031, 95% CI=0.946-1.124, p-value 0.482; TT vs CC+TC: OR= 0.945, 95% CI=0.827-1.080, p-value 0.403). Similarly, in the subgroup analysis by ethnicity, no association was found in Caucasian (C vs T: OR= 1.041, 95% CI=0.932-1.162, p-value 0.475; CC vs TC: OR= 1.031, 95% CI=0.951-1.118, p-value 0.464; CC vs TT: OR= 1.081, 95% CI=0.865-1.351, p-value 0.493; CC vs TT+TC: OR= 1.047, 95% CI=0.929-1.180, p-value 0.453; TT vs CC+TC: OR= 0.929, 95% CI=0.775-1.114, p-value 0.429;) and Asian populations (C vs T: OR= 1.004, 95% CI=0.908-1.111, p-value 0.931; CC vs TC: OR= 0.991, 95% CI=0.896-1.097, p-value 0.865; CC vs TT: OR= 1.015, 95% CI=0.848-1.214, p-value 0.871; CC vs TT+TC: OR= 1.000, 95% CI=0.909-1.101, p-value 0.994; TT vs CC+TC: OR= 0.967, 95% CI=0.808-1.159, p-value 0.720;). No evidence of publication bias was detected during the analysis. No significant association with breast cancer risk was demonstrated overall or on subgroup (Caucasian and Asian) analysis. It can be concluded that TGF-${\beta}1$ 29T/C polymorphism does not play a role in breast cancer susceptibility in overall or ethnicity-specific manner.


Meta-analysis;TGF-${\beta}1$ 29T/C;cancer;polymorphism;susceptibility


  1. Bouillon R, Carmeliet G, Verlinden L, et al (2008). Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev, 29, 726-76.
  2. Breast Cancer Association Consortium (2006). Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst, 98, 1382-96.
  3. Benson JR (2004). Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol, 5, 229-39.
  4. Bierie B, Moses HL (2006). Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer, 6, 506-20.
  5. Chen XH, Li XQ, Chen Y, et al (2011). Risk of aggressive breast cancer in women of Han nationality carrying TGFB1 rs1982073 C allele and FGFR2 rs1219648 G allele in North China. Breast Cancer Res Treat, 125, 575-82.
  6. Cox A, Dunning AM, Garcia-Closas M, et al (2007a). A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet, 39, 352-8.
  7. Cox DG, Penney K, Guo Q, et al (2007b). TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses' Health Study. BMC Cancer, 7, 175.
  8. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  9. Derynck R, Akhurst RJ, Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet, 29, 117-29.
  10. Desruisseau S, Palmari J, Giusti C, et al (2006). Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer, 94, 239-46.
  11. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.
  12. Dunning AM, Ellis PD, McBride S, et al (2003). A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res, 63, 2610-5.
  13. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
  14. Feigelson HS, Patel AV, Diver WR, et al (2006). Transforming growth factor beta receptor type I and transforming growth factor beta1 polymorphisms are not associated with postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev, 15, 1236-7.
  15. Fujii D, Brissenden JE, Derynck R, et al (1986). Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat Cell Mol Genet, 12, 281-8.
  16. Gonullu G, Basturk B, Evrensel T, et al (2007). Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J, 28, 1728-33.
  17. Gonzalez-Zuloeta Ladd AM, Arias-Vasquez A, Siemes C, et al (2007). Transforming-growth factor beta1 Leu10Pro polymorphism and breast cancer morbidity. Eur J Cancer, 43, 371-4.
  18. Grau AM, Wen W, Ramroopsingh DS, et al (2008). Circulating transforming growth factor-beta-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study. Breast Cancer Res Treat, 112, 335-41.
  19. Gu D, Zhuang L, Huang H, et al (2010). TGFB1 T29C polymorphism and breast cancer risk: a meta-analysis based on 10,417 cases and 11,455 controls. Breast Cancer Res Treat, 123, 857-61.
  20. Jin Q, Hemminki K, Grzybowska E, et al (2004). Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer, 112, 94-9.
  21. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
  22. Hishida A, Iwata H, Hamajima N, et al (2003). Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women. Breast Cancer, 10, 63-9.
  23. Huang Y, Li B, Qian J, et al (2010). TGF-beta1 29T/C polymorphism and breast cancer risk: a meta-analysis involving 25,996 subjects. Breast Cancer Res Treat, 123, 863-8.
  24. Joshi NN, Kale MD, Hake SS, et al (2011). Transforming growth factor beta signaling pathway associated gene polymorphisms may explain lower breast cancer risk in western Indian women. PLoS One, 6, 21866.
  25. Kaklamani VG, Baddi L, Liu J, et al (2005). Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res, 65, 3454-61.
  26. Krippl P, Langsenlehner U, Renner W, et al (2003). The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. Cancer Lett, 201, 181-4.
  27. Le Marchand L, Haiman CA, van den Berg D, et al (2004). T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev, 13, 412-5.
  28. Lee KM, Park SK, Hamajima N, et al (2005). Genetic polymorphisms of TGF-beta1 & TNF-beta and breast cancer risk. Breast Cancer Res Treat, 90, 149-55.
  29. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  30. Lichtenstein P, Holm NV, Verkasalo PK, et al (2000). Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med, 343, 78-85.
  31. Liu Y, Lin XF, Lin CJ, et al (2012). Transforming growth factor beta-1 C-509T polymorphism and cancer risk: a metaanalysis of 55 case-control studies. Asian Pac J Cancer Prev, 13, 4683-8.
  32. Ma X, Chen C, Xiong H, et al (2010). Transforming growth factorbeta1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls. Breast Cancer Res Treat, 124, 453-7.
  33. Massague J (2008). TGFbeta in Cancer. Cell, 134, 215-30.
  34. Pardali K, Moustakas A (2007). Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta, 1775, 21-62.
  35. Pooja S, Francis A, Rajender S, et al (2013). Strong impact of TGF-beta1 gene polymorphisms on breast cancer risk in Indian women: a case-control and population-based study. PLoS One, 8, 75979.
  36. Qi X, Zhang F, Yang X, et al (2010). Transforming growth factor-beta1 polymorphisms and breast cancer risk: a metaanalysis based on 27 case-control studies. Breast Cancer Res Treat, 122, 273-9.
  37. Qiu LX, Yao L, Mao C, et al (2010). TGFB1 L10P polymorphism is associated with breast cancer susceptibility: evidence from a meta-analysis involving 47,817 subjects. Breast Cancer Res Treat, 123, 563-7.
  38. Saha A, Gupta V, Bairwa NK, et al (2004). Transforming growth factor-beta1 genotype in sporadic breast cancer patients from India: status of enhancer, promoter, 5'-untranslated-region and exon-1 polymorphisms. Eur J Immunogenet, 31, 37-42.
  39. Quarmby S, Fakhoury H, Levine E, et al (2003). Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol, 79, 137-43.
  40. Rajkumar T, Samson M, Rama R, et al (2008). TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemoradiotherapy. Breast Cancer Res Treat, 112, 81-7.
  41. Roberts AB, Wakefield LM (2003). The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA, 100, 8621-3.
  42. Scola L, Vaglica M, Crivello A, et al (2006). Cytokine gene polymorphisms and breast cancer susceptibility. Ann N Y Acad Sci, 1089, 104-9.
  43. Shi HZ, Ren P, Lu QJ, et al (2012). Association between EGF, TGF-beta1 and TNF-alpha gene polymorphisms and hepatocellular carcinoma. Asian Pac J Cancer Prev, 13, 6217-20.
  44. Shin A, Shu XO, Cai Q, et al (2005). Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev, 14, 1567-70.
  45. Shu XO, Gao YT, Cai Q, et al (2004). Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res, 64, 836-9.
  46. Wu R, Li B (1999). A multiplicative-epistatic model for analyzing interspecific differences in outcrossing species. Biometrics, 55, 355-65.
  47. Vishnoi M, Pandey SN, Modi DR, et al (2008). Genetic susceptibility of epidermal growth factor +61A>G and transforming growth factor beta1 -509C>T gene polymorphisms with gallbladder cancer. Hum Immunol, 69, 360-7.
  48. Watanabe Y, Kinoshita A, Yamada T, et al (2002). A catalog of 106 single-nucleotide polymorphisms (SNPs) and 11 other types of variations in genes for transforming growth factor-beta1 (TGF-beta1) and its signaling pathway. J Hum Genet, 47, 478-83.
  49. Wei YS, Zhu YH, Du B, et al (2007). Association of transforming growth factor-beta1 gene polymorphisms with genetic susceptibility to nasopharyngeal carcinoma. Clin Chim Acta, 380, 165-9.
  50. Yamada Y (2001). Association of polymorphisms of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis. Pharmacogenetics, 11, 765-71.
  51. Zhang Y, Liu B, Jin M, et al (2009). Genetic polymorphisms of transforming growth factor-beta1 and its receptors and colorectal cancer susceptibility: a population-based casecontrol study in China. Cancer Lett, 275, 102-8.
  52. Zheng W (2009). Genetic polymorphisms in the transforming growth factor-beta signaling pathways and breast cancer risk and survival. Methods Mol Biol, 472, 265-77.
  53. Ziv E, Cauley J, Morin PA, et al (2001). Association between the T29-->C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: The Study of Osteoporotic Fractures. JAMA, 285, 2859-63.

Cited by

  1. Voltage-gated calcium channels: Novel targets for cancer therapy vol.14, pp.2, 2017,